Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963388 | 0.93 | ASIC3 (0.48) | HTR2AHTR2CHTR2BACACBHRH1 | |
| SCHEMBL23102124 | 0.87 | ACACB (0.43) | HTR2AHTR2CHTR2BACACBHRH1 | |
| SCHEMBL20665096 | 0.85 | TMEM97 (0.47) | HTR2AHTR2CHTR2BACACBHRH1 | |
| SCHEMBL23102118 | 0.84 | ACACB (0.44) | HTR2AHTR2CHTR2BACACBHRH1 | |
| SCHEMBL15142196 | 0.83 | DRD1 (0.54) | HRH3 | |
| SCHEMBL13499613 | 0.81 | HRH3 (0.43) | ASIC3HRH3NOTUMKCNH2AKR1C3 | |
| SCHEMBL21361596 | 0.79 | CARM1 (0.48) | HTR2AHTR2CHTR2BACACBASIC3 | |
| SCHEMBL24616867 | 0.79 | HSD17B3 (0.42) | ASIC3HRH3 | |
| SCHEMBL7894841 | 0.79 | KCNH2 (0.50) | HTR2AHTR2BASIC3HRH3NOTUM | |
| SCHEMBL12184930 | 0.79 | HRH3 (0.42) | ASIC3HRH3KCNH2AKR1C3AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2021-03-18 | — | — | US | disclosed |
| WO-2019178510-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | SEC61B, SEC61A1, SEC61G | HTR2A 4254/4885HTR2C 4577/4885HTR2B 3980/4885 |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | HTR2A 4166/4885HTR2C 4504/4885HTR2B 3951/4885 |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | HTR2A 4157/4885HTR2C 4460/4885HTR2B 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.